Andrew Shales

Andrew Shales is an experienced leader with a strong commercial background in the pharmaceutical, clinical laboratory and diagnostics businesses. He has specific expertise in strategic planning, commercial build-outs and launch execution with new companies & growth companies. In fact, Andrew has led three (3) startup pharma companies from inception to profitability (or twelve (12) month profitability trend) by their 3rd full year of operations. He has demonstrated success developing and leading high-performance commercial teams and managing successful domestic and international partnerships. Andrew’s teams share continuous focus on critical activities and operating efficiencies that achieve committed goals and establish category & company franchises. One of Andrew’s proudest accomplishments in this area is his Marketing team leadership of pre-launch and launch planning and execution for the anticonvulsant KEPPRA® (levetiracetam). KEPPRA is often cited as the product that really established UCB Pharma in the U.S. pharmaceutical market. Andrew has been responsible for launching or relaunching more than twenty (20) ethical pharma products including mega-brands as well as many niche brands. Mr. Shales holds a Bachelor’s degree from King’s College in Wilkes-Barre, PA and is currently enrolled in the part-time MSJ program in Pharmaceutical & Medical Device Law and Compliance at Seton Hall Law School.